Stevanato Group (NYSE:STVN) Posts Earnings Results, Misses Estimates By $0.01 EPS

Posted by Amber O'Connor on Nov 7th, 2024

Stevanato Group (NYSE:STVN – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported €0.12 ($0.13) EPS for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)), Briefing.com reports. Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The business had revenue of €277.90 million for the quarter, compared to analysts’ expectations of €274.36 million. During the same quarter in the prior year, the company posted $0.16 EPS. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. Stevanato Group updated its FY 2024 guidance to 0.517-0.539 EPS and its FY24 guidance to €0.47-0.49 EPS.

Stevanato Group Price Performance

STVN traded down €0.06 ($0.07) during trading on Thursday, reaching €22.49 ($24.71). 181,482 shares of the company’s stock were exchanged, compared to its average volume of 509,800. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.13 and a current ratio of 1.74. Stevanato Group has a 1 year low of €16.56 ($18.20) and a 1 year high of €34.73 ($38.16). The company’s fifty day simple moving average is €19.66 and its 200-day simple moving average is €20.31.

Analysts Set New Price Targets

Several brokerages have weighed in on STVN. Morgan Stanley lowered their price target on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Citigroup dropped their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th.

View Our Latest Analysis on Stevanato Group

About Stevanato Group

(Get Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.